JP2011520908A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520908A5
JP2011520908A5 JP2011509721A JP2011509721A JP2011520908A5 JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5 JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5
Authority
JP
Japan
Prior art keywords
phenyl
oxo
carboxamide
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509721A
Other languages
English (en)
Japanese (ja)
Other versions
JP5699075B2 (ja
JP2011520908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044034 external-priority patent/WO2009140549A1/en
Publication of JP2011520908A publication Critical patent/JP2011520908A/ja
Publication of JP2011520908A5 publication Critical patent/JP2011520908A5/ja
Application granted granted Critical
Publication of JP5699075B2 publication Critical patent/JP5699075B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509721A 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ Expired - Fee Related JP5699075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12775308P 2008-05-14 2008-05-14
US61/127,753 2008-05-14
PCT/US2009/044034 WO2009140549A1 (en) 2008-05-14 2009-05-14 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2011520908A JP2011520908A (ja) 2011-07-21
JP2011520908A5 true JP2011520908A5 (enExample) 2012-06-14
JP5699075B2 JP5699075B2 (ja) 2015-04-08

Family

ID=40908799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509721A Expired - Fee Related JP5699075B2 (ja) 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ

Country Status (7)

Country Link
US (2) US20110104161A1 (enExample)
EP (1) EP2288383A1 (enExample)
JP (1) JP5699075B2 (enExample)
AU (1) AU2009246263B2 (enExample)
CA (1) CA2723617A1 (enExample)
MX (1) MX2010012290A (enExample)
WO (1) WO2009140549A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 2−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TW201019961A (en) * 2008-10-17 2010-06-01 Genentech Inc Combination therapy
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
EP2480531B1 (en) 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CA2800998A1 (en) * 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
MX2012014776A (es) * 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
WO2012003338A1 (en) * 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AU2011307306A1 (en) * 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
WO2012042421A1 (en) * 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2680886B1 (en) * 2011-02-28 2016-08-10 Calitor Sciences, LLC Substituted quinoline compounds
KR20120100027A (ko) * 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
EP2692725A4 (en) 2011-03-29 2014-09-17 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6069312B2 (ja) * 2011-06-29 2017-02-01 アムジェン インコーポレイテッド 腎細胞癌の治療における生存の予測バイオマーカー
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
JP2015512447A (ja) * 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害薬の組合せおよびその使用
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
MA37700B1 (fr) 2012-06-26 2018-03-30 Bayer Pharma AG N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
JP6342392B2 (ja) * 2012-07-28 2018-06-13 カリター・サイエンシーズ・エルエルシー 置換型ピラゾロン化合物及び使用方法
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
US9718841B2 (en) * 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
JP6267619B2 (ja) * 2014-09-30 2018-01-24 学校法人近畿大学 慢性骨髄性白血病の治療用組成物
WO2016104617A1 (ja) * 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
EP3373932B1 (en) * 2015-11-14 2022-03-30 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN118994191A (zh) 2016-02-05 2024-11-22 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
PT3575293T (pt) 2017-01-26 2021-05-25 Ono Pharmaceutical Co Sal de etanossulfonato de n-{5-[(6,7-dimetoxi-4-quinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-quinolinocarboxamida
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CN117137915A (zh) 2017-02-15 2023-12-01 大鹏药品工业株式会社 医药组合物
EP3615522B1 (en) 2017-04-27 2021-08-04 Astrazeneca AB C5-anilinoquinazoline compounds and their use in treating cancer
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR102584306B1 (ko) 2017-09-08 2023-10-04 다이호야쿠힌고교 가부시키가이샤 항종양제 및 항종양 효과 증강제
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Axl阻害剤を有効成分として含む固形がん治療剤
CN111303024B (zh) 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
PE20230823A1 (es) * 2020-03-30 2023-05-19 Hutchison Medipharma Ltd Compuestos de amida y usos de los mismos
WO2021236718A1 (en) * 2020-05-20 2021-11-25 Fred Hutchinson Cancer Research Center Anti-fibrotic composition and related methods
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN117126142A (zh) * 2023-08-30 2023-11-28 遵义医科大学珠海校区 杂环类egfr突变抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DE102004035655A1 (de) * 2004-07-22 2006-02-16 Henkel Kgaa Verfahren zur Herstellung von Mehrphasen-Sticks für die WC-Reinigung
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989631B2 (en) * 2006-02-10 2011-08-02 Amgen Inc. Hydrate forms of AMG706
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Similar Documents

Publication Publication Date Title
JP2011520908A5 (enExample)
CA2605680A1 (en) Substituted amide derivatives as protein kinase inhibitors
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP2008521900A5 (enExample)
JPWO2020231808A5 (enExample)
CA2671744A1 (en) Compounds and compositions as protein kinase inhibitors
CA2587642A1 (en) Substituted heterocycles and methods of use
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2019504821A5 (enExample)
HRP20140265T1 (hr) Derivat aminopirazina i odgovarajuä†i lijek
MX2010012290A (es) Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
RU2014110172A (ru) Гетероциклическое производное и фармацевтическое средство
JP2014062093A5 (enExample)
JP2015500332A5 (enExample)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
SI3074386T1 (en) New aminopyrimidine derivatives
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
JP2017530185A5 (enExample)
IL295076A (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
JP2019523233A5 (enExample)
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
RU2014131378A (ru) Ингибиторы бромдомена
JP2006520805A5 (enExample)
JP2009515814A5 (enExample)
HRP20221454T1 (hr) Piridinamin-piridonski i pirimidinamin-piridonski spojevi